12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Masitinib: Phase II data

Researchers at the University of Lille Nord de France and colleagues reported data from a double-blind, French Phase II trial in 30 evaluable patients with progressive MS showing that once-daily 3-6 mg/kg oral masitinib non-significantly improved mean MSFC scores, the primary endpoint, from baseline to 12 months by 103% vs. a 60% reduction...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >